Brief: Oncopeptides Receives Positive Opinion By CHMP On Type II Variation To Extend Therapeutic Indication Of Pepaxti

Oncopeptides AB

14/09/2023 14:56

Sept 14 (Reuters) - Oncopeptides AB  ONCO.ST :
    * CHMP ISSUES POSITIVE OPINION ON TYPE II VARIATION TO EXTEND THE THERAPEUTIC INDICATION OF
PEPAXTI BASED ON OCEAN TRIAL RESULTS
    * CHMP RECOMMENDS THAT USE OF PEPAXTI COULD BE EXPANDED TO EARLIER LINES OF TREATMENT AND
ALSO
PERIPHERAL ADMINISTRATION
    * WILL AS A NEXT STEP ASSESS CURRENT MARKET DYNAMICS OF RAPIDLY EVOLVING MULTIPLE MYELOMA
LANDSCAPE
    * WILL ASSES EFFECT EXTENDING PEPAXTI INTO EARLIER LINES OF TREATMENT WOULD HAVE ON CO'S
ABILITY
TO RECEIVE REIMBURSED PRICE


Source text for Eikon:  ID:nMFNxZSPp 
Further company coverage:  ONCO.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))